# Insmed (INSM) — Analyst Forecast

INSM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/insm/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 24 | 1 | 0 | 25 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $169.00 | $191.90 | $220.00 | 10 |

Last price $99.21 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | HC Wainwright & Co. | Maintained | Buy | $220.00 |
| Oct 12, 2026 | Wolfe Research | Downgraded | Outperform → Peer Perform | — |
| Sep 30, 2026 | Barclays | Maintained | Overweight | $207.00 |
| Sep 24, 2026 | Goldman Sachs | Maintained | Buy | $188.00 |
| Sep 15, 2026 | Roth Capital | Maintained | Buy | $198.00 |
| Aug 10, 2026 | Truist Securities | Maintained | Buy | $195.00 |
| Aug 10, 2026 | JP Morgan | Maintained | Overweight | $175.00 |
| Aug 7, 2026 | Wells Fargo | Maintained | Overweight | $169.00 |
| Aug 7, 2026 | Evercore ISI Group | Maintained | Outperform | $170.00 |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | $205.00 |
| Jul 21, 2026 | BMO Capital | Initiated Coverage | Outperform | $192.00 |
| Jul 15, 2026 | Wells Fargo | Maintained | Overweight | $161.00 |
| Jul 10, 2026 | Guggenheim | Maintained | Buy | $207.00 |
| Jun 22, 2026 | Evercore ISI Group | Maintained | Outperform | $160.00 |
| Jun 8, 2026 | JP Morgan | Maintained | Overweight | $179.00 |
| Jun 5, 2026 | RBC Capital | Maintained | Outperform | $195.00 |
| May 14, 2026 | Truist Securities | Maintained | Buy | $185.00 |
| May 8, 2026 | Guggenheim | Maintained | Buy | $226.00 |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | $160.00 |
| May 8, 2026 | RBC Capital | Maintained | Outperform | $205.00 |

## Frequently Asked Questions

### What is the price target for INSM stock?

The average 12-month analyst price target for Insmed (INSM) is $191.90, with a high estimate of $220.00 and a low of $169.00, across 10 analysts.

### Is INSM a buy, sell, or hold?

Analysts covering Insmed currently average a Buy rating: 24 buy, 1 hold and 0 sell, from 25 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for INSM?

The average price target of $191.90 implies 93.43% upside from the last price of $99.21.

### What is the latest analyst rating on INSM?

On Oct 12, 2026, HC Wainwright & Co. maintained Insmed at Buy with a price target of $220.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).